Corton Capital’s Fulcrum Therapeutics FULC Stock Holding History

Corton Capital’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,498	Closed	-$110K	–	260
2024 Q4	$110K	Sell	23,498 -34,101	-59%	-$126K	0.06%	340
2024 Q3	$206K	Buy	57,599 +31,427	+120%	+$233K	0.1%	365
2024 Q2	$162K	Buy	26,172 +13,719	+110%	+$104K	0.09%	406
2024 Q1	$118K	Buy	+12,453	New	+$111K	0.04%	467
2023 Q2	–	Sell	-13,441	Closed	-$38.3K	–	464
2023 Q1	$38.3K	Buy	13,441 +1,876	+16%	+$16.8K	0.03%	314
2022 Q4	$84.2K	Buy	+11,565	New	+$75.4K	0.07%	278
2022 Q3	–	Sell	-10,759	Closed	-$53K	–	303
2022 Q2	$53K	Buy	10,759 +847	+9%	+$8.28K	0.05%	310
2022 Q1	$234K	Buy	+9,912	New	+$140K	0.1%	311

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's FULC Position: Q1 2025 in Review

Corton Capital sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 23,498 shares — an estimated $110K sold.

Corton Capital first reported a position in FULC in Q1 2022 and held it in 8 quarters. The position peaked at $234K in Q1 2022. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

Corton Capital reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
Corton Capital sold 23,498 Fulcrum Therapeutics shares in Q1 2025, an estimated $110K.
Corton Capital first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 8 quarters.
Corton Capital's Fulcrum Therapeutics position peaked at $234K in Q1 2022.
117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.